
Wanbury Ltd is Rated Sell by MarketsMOJO
2026-11-10 10:10:43Wanbury Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 November 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Read MoreWanbury Gains 4.87% This Week: Mixed Financials and Volatile Trading Shape Performance
2026-11-07 14:04:24Key Events This Week Nov 2: Week opens at Rs.190.15 with modest gains Nov 3: Continued upward momentum to Rs.192.65 (+1.31%) Nov 4: Slight dip to Rs.192.55 amid cautious trading Nov 5: Quarterly results released; stock plunges 3.19% to Rs.186.40 Nov 6: Strong recovery with 6.76% surge to Rs.199.00 Week OpenRs.189.75 <div class...
Read More
Wanbury Ltd Reports Flat Quarterly Performance Amid Mixed Financial Trends
2026-11-05 11:01:00Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has posted a flat financial performance for the quarter ended September 2026, signalling a stabilisation after a period of decline. While net sales and operating profit metrics reached new highs, the company’s profitability took a hit with a notable contraction in net profit after tax, reflecting ongoing challenges in margin management.
Read MoreWanbury Ltd Gains 6.30%: Valuation Upgrade Amid Mixed Financial Signals
2026-10-31 14:03:53Key Events This Week 26 Oct: Sharp 6.44% decline on valuation shift news 27 Oct: Upgrade to Sell rating on improved valuation 29 Oct: Stock gains 3.02% amid mixed financial trends 30 Oct: Week closes with 5.10% daily gain, outperforming Sensex Week OpenRs.178.50 Week CloseRs.189.75<div cl...
Read More
Wanbury Ltd Upgraded to Sell on Improved Valuation Amid Mixed Financial Trends
2026-10-27 08:46:22Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 26 Oct 2026. This change reflects a nuanced reassessment of the company’s valuation, quality, financial trends, and technical outlook amid ongoing operational headwinds and market underperformance.
Read More
Wanbury Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Market Challenges
2026-10-26 08:01:38Wanbury Ltd’s recent valuation adjustments have repositioned the pharmaceutical company as an attractive investment opportunity, despite ongoing sector headwinds and a challenging price performance relative to the broader market. The company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have notably improved, signalling a potential value play for discerning investors.
Read More
Wanbury Ltd is Rated Strong Sell
2026-10-16 10:11:10Wanbury Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 October 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Wanbury Ltd Valuation Shifts Amidst Sector Volatility: A Detailed Analysis
2026-10-13 08:00:47Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from very attractive to fair, reflecting a nuanced change in market perception. Despite a recent downgrade to a Strong Sell rating, the company’s valuation metrics remain compelling relative to its peers, though caution is warranted given recent price declines and sector dynamics.
Read MoreWanbury Ltd Gains 3.46%: 2 Key Technical Factors Driving the Week
2026-10-10 14:02:00Key Events This Week 5 Oct: Death Cross formation signals potential bearish trend 6 Oct: Wanbury faces intensified bearish momentum amid technical downshift 9 Oct: Week closes at Rs.195.85, up 3.46% for the week Week OpenRs.189.30 Week CloseRs.195.85+3.46% <div class...
Read MoreAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
20-Nov-2026 | Source : BSEWanbury Limiteds Tanuka API Facility Successfully Completes South Korea MFDS cGMP Inspection with Zero Observations
Announcement under Regulation 30 (LODR)-Investor Presentation
18-Nov-2026 | Source : BSEDisclosure under Regulation 30 of the SEBI LODR 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16-Nov-2026 | Source : BSEWanbury Limiteds Tanuku Plant - US FDA Inspection - Updates
Corporate Actions
No Upcoming Board Meetings
Wanbury Ltd has declared 10% dividend, ex-date: 29 Jul 10
No Splits history available
No Bonus history available
No Rights history available